First U.S. Patient Treated Following FDA Clearance of NeoTract’s UroLift® System

PLEASANTON, Calif. – NeoTract, Inc., today announced that the first patient in the United States has been treated with its commercial UroLift® System, the first permanent implant to treat symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men 50 years of age or older. Cleared by the U.S. Food and Drug Administration on September 13, 2013, the UroLift System is designed to relieve symptoms caused by an enlarged prostate, while preserving sexual function. … Continue reading First U.S. Patient Treated Following FDA Clearance of NeoTract’s UroLift® System